Recently, Alibaba's AI model, DAMO PANDA, received the "Breakthrough Device" designation from the U.S. Food and Drug Administration (FDA). This achievement marks a significant breakthrough in early pancreatic cancer screening, offering new possibilities for early diagnosis of this deadly disease.
DAMO PANDA, developed by Alibaba's DAMO Academy, is an AI model specifically designed for pancreatic cancer screening. Its primary function is to accurately identify subtle lesions in plain CT scans that are often imperceptible to the human eye. This technology aims to address the challenge of early pancreatic cancer detection, a disease often called the "king of cancers" due to its high mortality rate and low early detection probability.
